News

An independent DSMB has also recommended continued enrollment in the trial’s first cohort.

Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.

No serious adverse events deemed related to RGX-314 occurred in the treated patients.

Encouraging efficacy signals have also been observed in treated participants.

Significant reductions in pain were reported for patients who received rexlemestrocel-L+HA in comparison to patients who received a saline control.

The trial will take place at the University of Miami Health System and will be carried out in collaboration with the Diabetes Research Institute.

The professor and director of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at University of Washington School of Medicine discussed the paper he recently coauthored.

Review top news and interview highlights from the week ending February 10, 2023.

The updated data included a median overall survival of 26 months after treatment with brexu-cel.

The POLARIS study adds to the growing body of evidence validating GPRC5D as a target for CAR T-cell therapy in R/R MM.

Mehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.

The FDA cleared Century’s IND for CNTY-101 in August 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The new findings are consistent with previous research, in which ophNdi1 demonstrated benefit in AMD models.

The director of the CCU/ICU at Saint John’s Health Center discussed a possible more collaborative approach to treating patients in the future.

A pivotal phase 2 clinical trial for RP-A501 is expected to initiate in Q2 2023.

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

Patients treated with ALLO-715 achieved an ORR of 55.8%.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

GC012F recently showed efficacy in newly-diagnosed MM in investigator-initiated trials.

The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

The clinical hold comes a few weeks after the company announced it was stopping enrollment in the phase 1/2 clinical trial.

Mehra and Subramanian discussed preclinical research with the investigational gene therapy SLS-004.

The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.

Cartesian Therapeutics’ Descartes-08 will be administered as 6 weekly infusions and does not require preconditioning chemotherapy.

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Decibel Therapeutics expects the trial for DB-OTO to begin in the first half of 2023.